CLINICAL TRIAL: DFMO AND SULDINAC IN COLON POLYPS

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 本研究的目的是确定每日口服DFMO 500 mg加舒丁酸150 mg是否能减少结肠息肉的发生。参与这项研究的一半受试者将在36个月内服用这种药物组合，并将其与安慰剂进行比较。此外，这项研究将确定这些药物在服用这些剂量时的安全性。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to determine whether the combination of DFMO 500mg plus Suldinac 150mg/day taken by mouth every day, will decrease the development of colon polyps. The combination of drugs will be given over 36 months to half of the subjects participating in this study, and will be compared to placebo. Also, this study will determine the safety of these drugs when taken at theses doses.